US 11,958,842 B2
Substituted phenazines and methods of treating cancer and bacterial diseases
Pål Rongved, Oslo (NO); Ove Alexander Høgmoen Åstrand, Haslum (NO); Elvar Ørn Viktorsson, Oslo (NO); Ørjan Samuelson, Tromsø (NO); Adam Heikal, Kolsås (NO); Ole Andreas Løchen Økstad, Moss (NO); and Geir Kildahl-Andersen, Oslo (NO)
Assigned to ADJUTEC PHARMA AS, Oslo (NO)
Filed by Adjutec Pharma AS, Oslo (NO)
Filed on Apr. 26, 2021, as Appl. No. 17/239,976.
Application 17/239,976 is a continuation of application No. 16/469,948, granted, now 11,046,678, previously published as PCT/GB2017/053787, filed on Dec. 18, 2017.
Claims priority of application No. 1621520 (GB), filed on Dec. 16, 2016.
Prior Publication US 2021/0292313 A1, Sep. 23, 2021
Int. Cl. A61K 31/498 (2006.01); A61K 47/68 (2017.01); A61P 31/04 (2006.01); A61P 35/00 (2006.01); C07D 241/46 (2006.01); C07D 241/52 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 413/12 (2006.01); A61K 45/06 (2006.01)
CPC C07D 413/12 (2013.01) [A61K 47/68 (2017.08); A61P 31/04 (2018.01); A61P 35/00 (2018.01); C07D 241/52 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); A61K 45/06 (2013.01)] 6 Claims
 
1. A combination product comprising:
meropenem; and
a compound of the following formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.
 
2. A pharmaceutical composition comprising the combination product according to claim 1 together with at least one pharmaceutically acceptable carrier or excipient.